7
Registered trials
1
Recruiting
7
Unique sponsors
4
Unique IMPs
5
Commercial trials
Drug classes (ATC)
—
ATC code not specified
5
N
Neurology/Psychiatry (ATC N)
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
4 substances
Phase III:
1
Phase II:
2
Phase I (Other):
4
Phase III
1 trial-
EndedUCB Biopharma CommercialLACOSAMIDE
Phase II
2 trials-
EndedEisai Limited CommercialPERAMPANEL
-
EndedAzienda Ospedaliera Universitaria Meyer IRCCS AcademicCANNABIDIOL
Phase I (Other)
4 trials-
PendingAngelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. CommercialIMP not specified
-
RecruitingQuralis Corp. CommercialIMP not specified
-
EndedRapport Therapeutics Inc. CommercialIMP not specified
-
EndedTrevena Inc. AcademicTRV045
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | Commercial | 1 | Phase I (Other) | 0 |
| Quralis Corp. | Commercial | 1 | Phase I (Other) | 1 |
| Rapport Therapeutics Inc. | Commercial | 1 | Phase I (Other) | 0 |
| Eisai Limited | Commercial | 1 | Phase II | 0 |
| UCB Biopharma | Commercial | 1 | Phase III | 0 |
| Trevena Inc. | Academic | 1 | Phase I (Other) | 0 |
| Azienda Ospedaliera Universitaria Meyer IRCCS | Academic | 1 | Phase II | 0 |
New trials by year
2019
1
2020
1
2023
1
2024
2
2026
1